{"filing":{"accession_number":"0001437402-26-000043","cik":"0001437402","ticker":"ARDX","company_name":"ARDELYX, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ardx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/ardx-20260806.htm"},"events":[{"id":25732,"run_id":23352,"accession_number":"0001437402-26-000043","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Ardelyx disclosed Q2 2026 financial results with total product revenue of $118.1 million (31% YoY growth), including IBSRELA revenue of $86.2 million (33% growth) and XPHOZAH revenue of $31.9 million (27% growth), along with a net loss of $16.7 million and revised FY 2026 guidance. The earnings release and presentation were furnished as exhibits and include condensed financial statements and management commentary.","company_name":"ARDELYX, INC.","ticker":"ARDX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26636,"accession_number":"0001437402-26-000043","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Ardelyx. The filing announces total product revenue of $118.1 million (31% YoY growth), with detailed breakdowns for IBSRELA ($86.2 million, 33% growth) and XPHOZAH ($31.9 million, 27% growth), along with operating expenses, net loss of $16.7 million, and revised FY 2026 guidance. The press release is furnished as Exhibit 99.1 and includes condensed financial statements and management commentary typical of quarterly earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:26:16.831931+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26637,"accession_number":"0001437402-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces Q2 2026 financial results for the quarter ended June 30, 2026, with an earnings presentation furnished as Exhibit 99.2. The press release (EX-99.1) reports total product revenue of $118.1 million (31% YoY growth), revised FY 2026 guidance, and updated long-term outlook. This is a standard earnings release disclosure, material to investors assessing the company's financial performance and revised guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:26:16.831931+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26636,"accession_number":"0001437402-26-000043","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Ardelyx. The filing announces total product revenue of $118.1 million (31% YoY growth), with detailed breakdowns for IBSRELA ($86.2 million, 33% growth) and XPHOZAH ($31.9 million, 27% growth), along with operating expenses, net loss of $16.7 million, and revised FY 2026 guidance. The press release is furnished as Exhibit 99.1 and includes condensed financial statements and management commentary typical of quarterly earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:26:16.831931+00:00","company_name":"ARDELYX, INC.","ticker":"ARDX","filing_date":"2026-08-06"},{"id":26637,"accession_number":"0001437402-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces Q2 2026 financial results for the quarter ended June 30, 2026, with an earnings presentation furnished as Exhibit 99.2. The press release (EX-99.1) reports total product revenue of $118.1 million (31% YoY growth), revised FY 2026 guidance, and updated long-term outlook. This is a standard earnings release disclosure, material to investors assessing the company's financial performance and revised guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:26:16.831931+00:00","company_name":"ARDELYX, INC.","ticker":"ARDX","filing_date":"2026-08-06"}]}